"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010879
|
| MeSH Number(s) |
D03.383.606
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperazines".
Below are MeSH descriptors whose meaning is more specific than "Piperazines".
This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1999 | 4 | 0 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 2 | 2 | 4 |
| 2003 | 2 | 0 | 2 |
| 2004 | 5 | 1 | 6 |
| 2005 | 1 | 0 | 1 |
| 2006 | 7 | 1 | 8 |
| 2007 | 3 | 4 | 7 |
| 2008 | 11 | 2 | 13 |
| 2009 | 2 | 3 | 5 |
| 2010 | 5 | 2 | 7 |
| 2011 | 3 | 3 | 6 |
| 2012 | 1 | 2 | 3 |
| 2013 | 5 | 3 | 8 |
| 2014 | 3 | 4 | 7 |
| 2015 | 6 | 3 | 9 |
| 2016 | 1 | 2 | 3 |
| 2017 | 3 | 2 | 5 |
| 2018 | 1 | 6 | 7 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 7 | 8 |
| 2021 | 4 | 5 | 9 |
| 2022 | 1 | 4 | 5 |
| 2023 | 1 | 0 | 1 |
| 2024 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperazines" by people in Profiles.
-
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Oncologist. 2024 Dec 06; 29(12):1032-1043.
-
Real-world quality-of-life of patients with HR+/HER2-?advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Res Treat. 2025 Feb; 209(3):613-627.
-
Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024 Nov 22; 79(5):1258-1261.
-
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Target Oncol. 2024 Nov; 19(6):879-892.
-
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct; 8:e2400477.
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
-
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib. J Comp Eff Res. 2024 Oct; 13(10):e240111.
-
Crizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing Autophagy. Mol Cancer Res. 2024 09 04; 22(9):840-851.
-
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). JCO Precis Oncol. 2024 Sep; 8:e2400418.
-
Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. Elife. 2024 Aug 30; 13.